Gossamer Bio, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| By: | /s/ Faheem Hasnain |
| Faheem Hasnain | |
| President and Chief Executive Officer | |
| Date | March 17, 2026 |
SIGNATURES AND POWER OF ATTORNEY
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Faheem Hasnain | President, Chief Executive Officer and Chairman of the Board of Directors(principal executive officer) | March 17, 2026 |
| Faheem Hasnain | ||
| /s/ Bryan Giraudo | Chief Operating Officer and Chief Financial Officer(principal financial andaccounting officer) | March 17, 2026 |
| Bryan Giraudo | ||
| /s/ Russell Cox | Director | March 17, 2026 |
| Russell Cox | ||
| /s/ Thomas Daniel, M.D. | Director | March 17, 2026 |
| Thomas Daniel, M.D. | ||
| /s/ Sky Drynan | Director | March 17, 2026 |
| Sky Drynan | ||
| /s/ Sandra Milligan, M.D., J.D. | Director | March 17, 2026 |
| Sandra Milligan, M.D., J.D. | ||
| /s/ Steven Nathan, M.D. | Director | March 17, 2026 |
| Steven Nathan, M.D. | ||
| /s/ John Quisel, J.D., Ph.D. | Director | March 17, 2026 |
| John Quisel, J.D., Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.